Advanced in Virilizing Ovarian Tumor

Dr. Ira S. Winer

Gynecologic Oncology | Obstetrics and Gynecology | Oncology
University Physician Group
4100 John R St, 
Detroit, MI 
 (695.6 mi)
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Advanced in Virilizing Ovarian Tumor
University Physician Group
4100 John R St, 
Detroit, MI 
 (695.6 mi)
OverviewInsuranceLocationsClinical Research

Overview

Ira Winer is a Gynecologic Oncologist and an Obstetrics and Gynecologist in Detroit, Michigan. Dr. Winer and is rated as an Advanced provider by MediFind in the treatment of Virilizing Ovarian Tumor. His top areas of expertise are Ovarian Cancer, Endometrial Cancer, Vulvar Cancer, Vaginectomy, and Tubal Ligation. Dr. Winer is currently accepting new patients.

His clinical research consists of co-authoring 45 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Gynecologic Oncology
Obstetrics and Gynecology
Oncology
Licenses
Obstetrics & Gynecology in MI
Hospital Affiliations
Karmanos Cancer Center
Harper University Hospital
Languages Spoken
English
Hebrew
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Priority Health
  •  Blue Cross Blue Shield
  •  McLaren Health
  •  UnitedHealthcare
  •  Humana

Locations

UNIVERSITY PHYSICIAN GROUP
4100 John R St, Detroit, MI 48201

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

Assessment of Carboplatin Clearance Predictors: A PK Study on NCI-Sponsored Clinical Trials or Standard of Care Treatments Using Carboplatin
Assessment of Carboplatin Clearance Predictors: A PK Study on NCI-Sponsored Clinical Trials or Standard of Care Treatments Using Carboplatin
Enrollment Status: Recruiting
Publish Date: July 12, 2024
Intervention Type: Drug, Procedure
Study Phase: Phase 1
Phase 1 Dose Escalation and Expansion Cohort of Carboplatin and Gemcitabine With or Without M6620 (VX-970) in First or Second Recurrence Platinum-Sensitive Epithelial Ovarian, Peritoneal, and Fallopian Tube Cancer
Phase 1 Dose Escalation and Expansion Cohort of Carboplatin and Gemcitabine With or Without M6620 (VX-970) in First or Second Recurrence Platinum-Sensitive Epithelial Ovarian, Peritoneal, and Fallopian Tube Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 21, 2025
Intervention Type: Drug, Other
Study Drugs: Berzosertib, Carboplatin, Gemcitabine
Study Phase: Phase 1
Phase 2 Study of M6620 (VX-970) in Combination With Gemcitabine Versus Gemcitabine Alone in Subjects With Platinum-Resistant Recurrent Ovarian or Primary Peritoneal Fallopian Tube Cancer
Phase 2 Study of M6620 (VX-970) in Combination With Gemcitabine Versus Gemcitabine Alone in Subjects With Platinum-Resistant Recurrent Ovarian or Primary Peritoneal Fallopian Tube Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 07, 2025
Intervention Type: Drug
Study Phase: Phase 2
A Randomized Phase 2 Study of Bevacizumab and Either Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant or Platinum Refractory Ovarian Cancer
A Randomized Phase 2 Study of Bevacizumab and Either Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant or Platinum Refractory Ovarian Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 17, 2025
Intervention Type: Biological, Drug
Study Drugs: Anetumab ravtansine, Bevacizumab, Paclitaxel
Study Phase: Phase 2
Phase I Dose-Escalation Bioavailability Study of Oral Triapine in Combination With Concurrent Chemoradiation for Locally Advanced Cervical Cancer (LACC) and Vaginal Cancer
Phase I Dose-Escalation Bioavailability Study of Oral Triapine in Combination With Concurrent Chemoradiation for Locally Advanced Cervical Cancer (LACC) and Vaginal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: November 19, 2024
Intervention Type: Procedure, Drug, Radiation, Other
Study Drugs: Cisplatin, Triapine
Study Phase: Phase 1
A Phase II Study of the PARP Inhibitor Olaparib in Combination With the DNA Damaging Agent Temozolomide for the Treatment of Advanced Uterine Leiomyosarcoma
A Phase II Study of the PARP Inhibitor Olaparib in Combination With the DNA Damaging Agent Temozolomide for the Treatment of Advanced Uterine Leiomyosarcoma
Enrollment Status: Active_not_recruiting
Publish Date: October 15, 2024
Intervention Type: Procedure, Drug
Study Drugs: Olaparib, Temozolomide
Study Phase: Phase 2
A Phase 1b/2, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients With Solid Tumors Likely to Express NaPi2b
A Phase 1b/2, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients With Solid Tumors Likely to Express NaPi2b
Enrollment Status: Active_not_recruiting
Publish Date: November 13, 2023
Intervention Type: Drug
Study Drug: Upifitamab rilsodotin
Study Phase: Phase 1/Phase 2
ARIEL4 (Assessment of Rucaparib In Ovarian CancEr TriaL): A Phase 3 Multicenter, Randomized Study of Rucaparib Versus Chemotherapy in Patients With Relapsed, BRCA Mutant, High Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
ARIEL4 (Assessment of Rucaparib In Ovarian CancEr TriaL): A Phase 3 Multicenter, Randomized Study of Rucaparib Versus Chemotherapy in Patients With Relapsed, BRCA Mutant, High Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Enrollment Status: Completed
Publish Date: June 09, 2023
Intervention Type: Drug
Study Drugs: Chemotherapy, Rucaparib
Study Phase: Phase 3
A Phase 1/2a Study to Evaluate the Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine in Adult Patients With Selected Solid Tumors
A Phase 1/2a Study to Evaluate the Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine in Adult Patients With Selected Solid Tumors
Enrollment Status: Completed
Publish Date: April 19, 2022
Intervention Type: Drug, Biological
Study Drugs: GEN-009 Adjuvant Vaccine, Nivolumab, Pembrolizumab
Study Phase: Phase 1/Phase 2
A Phase 3, Randomized, Single Dose, Open-Label Study to Investigate the Safety and Efficacy of OTL38 Injection (OTL38) for Intra-operative Imaging of Folate Receptor Positive Ovarian Cancer
A Phase 3, Randomized, Single Dose, Open-Label Study to Investigate the Safety and Efficacy of OTL38 Injection (OTL38) for Intra-operative Imaging of Folate Receptor Positive Ovarian Cancer
Enrollment Status: Completed
Publish Date: February 04, 2022
Intervention Type: Procedure, Device, Drug
Study Phase: Phase 3
Study of Serum Measured Folate Receptor and Its Induction as a Biomarker in the Diagnosis and Surveillance of Ovarian Carcinoma
Study of Serum Measured Folate Receptor and Its Induction as a Biomarker in the Diagnosis and Surveillance of Ovarian Carcinoma
Enrollment Status: Completed
Publish Date: August 14, 2019
Intervention Type: Other, Drug
Study Phase: Phase 1
View 10 Less Clinical Trials

45 Total Publications

Nemvaleukin alfa, a modified interleukin-2 cytokine, as monotherapy and with pembrolizumab in patients with advanced solid tumors (ARTISTRY-1).
Nemvaleukin alfa, a modified interleukin-2 cytokine, as monotherapy and with pembrolizumab in patients with advanced solid tumors (ARTISTRY-1).
Journal: Journal for immunotherapy of cancer
Published: October 11, 2024
Similar Doctors
Distinguished in Virilizing Ovarian Tumor
Dr. Robert T. Morris
Gynecologic Oncology | Oncology | Obstetrics and Gynecology
Distinguished in Virilizing Ovarian Tumor
Dr. Robert T. Morris
Gynecologic Oncology | Oncology | Obstetrics and Gynecology

Ascension St John Hospital

22101 Moross Rd, 
Detroit, MI 
 (8.7 mi)
586-753-0011
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Robert Morris is a Gynecologic Oncologist and an Oncologist in Detroit, Michigan. Dr. Morris and is rated as a Distinguished provider by MediFind in the treatment of Virilizing Ovarian Tumor. His top areas of expertise are Cervical Cancer, Neuroendocrine Carcinoma of the Cervix, Malignant Mixed Mullerian Tumor, Oophorectomy, and Gastrostomy. Dr. Morris is currently accepting new patients.

Distinguished in Virilizing Ovarian Tumor
Dr. Garth D. Phibbs
Gynecologic Oncology | Surgical Oncology | Obstetrics and Gynecology
Distinguished in Virilizing Ovarian Tumor
Dr. Garth D. Phibbs
Gynecologic Oncology | Surgical Oncology | Obstetrics and Gynecology
2109 Hughes Dr, Suite 820, 
Toledo, OH 
 (54.3 mi)
419-471-2025
Languages Spoken:
English, French
See accepted insurances
Accepting New Patients

Garth Phibbs is a Gynecologic Oncologist and a Surgical Oncologist in Toledo, Ohio. Dr. Phibbs and is rated as a Distinguished provider by MediFind in the treatment of Virilizing Ovarian Tumor. His top areas of expertise are Malignant Mixed Mullerian Tumor, Endometrial Cancer, Ovarian Cancer, Hernia Surgery, and Salpingo-Oophorectomy. Dr. Phibbs is currently accepting new patients.

Distinguished in Virilizing Ovarian Tumor
Dr. Michael L. Hicks
Gynecologic Oncology | Oncology | Obstetrics and Gynecology
Distinguished in Virilizing Ovarian Tumor
Dr. Michael L. Hicks
Gynecologic Oncology | Oncology | Obstetrics and Gynecology
44405 Woodward Ave, Suite 202, 
Pontiac, MI 
 (21.3 mi)
248-858-2270
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Michael Hicks is a Gynecologic Oncologist and an Oncologist in Pontiac, Michigan. Dr. Hicks and is rated as a Distinguished provider by MediFind in the treatment of Virilizing Ovarian Tumor. His top areas of expertise are Cervical Cancer, Malignant Mixed Mullerian Tumor, Neuroendocrine Carcinoma of the Cervix, Hysterectomy, and Bladder Reconstruction. Dr. Hicks is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile